TCGA-97-8552-01A-11R-2403-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 55
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.360
- KRAS_SIGNALING_DN+0.360
- COAGULATION+0.330
- MYOGENESIS+0.280
- PANCREAS_BETA_CELLS+0.180
- KRAS_SIGNALING_UP+0.150
- XENOBIOTIC_METABOLISM+0.150
- INFLAMMATORY_RESPONSE+0.130
- HEDGEHOG_SIGNALING+0.080
- ESTROGEN_RESPONSE_EARLY+0.070
Top 10 suppressed
- MYC_TARGETS_V1-0.720
- E2F_TARGETS-0.700
- G2M_CHECKPOINT-0.690
- MYC_TARGETS_V2-0.680
- MTORC1_SIGNALING-0.590
- UNFOLDED_PROTEIN_RESPONSE-0.570
- OXIDATIVE_PHOSPHORYLATION-0.500
- PROTEIN_SECRETION-0.500
- MITOTIC_SPINDLE-0.480
- DNA_REPAIR-0.450
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_9F09XV62 | low-grade glioma | — | 0.941 |
| 2 | TCGA-G2-A2EK-01A-22R-A18C-07 | — | — | 0.938 |
| 3 | TCGA-62-8397-01A-11R-2326-07 | — | cohortA1 | 0.934 |
| 4 | TCGA-97-A4M1-01A-11R-A24X-07 | — | cohortA1 | 0.932 |
| 5 | BS_ERJAJ0KA | Ganglioglioma | — | 0.930 |
| 6 | SRR1381673 | GTEX | — | 0.930 |
| 7 | SJEPD014_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.928 |
| 8 | BS_0X9EGHY2 | low-grade glioma | — | 0.922 |
| 9 | BS_YZ2Z1Q6Y | pilocytic astrocytoma | — | 0.921 |
| 10 | BS_EXYHZ6D4 | pilocytic astrocytoma | — | 0.920 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.360 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.360 | Remibrutinib | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.150 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.130 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| COMPLEMENT | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.050 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |